Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

MLA

Douillard, Jean-Yves, et al. “Randomized, Phase III Trial of Panitumumab with Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) versus FOLFOX4 Alone as First-Line Treatment in Patients with Previously Untreated Metastatic Colorectal Cancer: The PRIME Study.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 28, no. 31, Nov. 2010, pp. 4697–705. EBSCOhost, https://doi.org/10.1200/JCO.2009.27.4860.

APA

Douillard, J.-Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., Rivera, F., Kocákova, I., Ruff, P., Błasińska-Morawiec, M., Šmakal, M., Canon, J.-L., Rother, M., Oliner, K. S., Wolf, M., & Gansert, J. (2010). Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 28(31), 4697–4705. https://doi.org/10.1200/JCO.2009.27.4860

Chicago

Douillard, Jean-Yves, Salvatore Siena, James Cassidy, Josep Tabernero, Ronald Burkes, Mario Barugel, Yves Humblet, et al. 2010. “Randomized, Phase III Trial of Panitumumab with Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) versus FOLFOX4 Alone as First-Line Treatment in Patients with Previously Untreated Metastatic Colorectal Cancer: The PRIME Study.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 28 (31): 4697–4705. doi:10.1200/JCO.2009.27.4860.